Dichos y Refranes

Descargar Mr Nice en DOCX

Mr Nice DOCX, página 6

Mr Nice: 15700 Libros DOCX

  1. Sin título

     
    Tipo: Microsoft Word
    NICE recommends assessing response to TNFi after 12 weeks [38]; secukinumab, bimekizumab and JAKis after 16 weeks [39–42]; and ixekizumab after 16-20 weeks ... Sin título.
    https://library.educause.edu/-/media/files/library/2019/3/xrwebinarchat29mar2019.docx
  2.  
    Tipo: Microsoft Word

  3. Sin título

     
    Tipo: Microsoft Word
    NICE recommends assessing response to TNFi after 12 weeks [38]; secukinumab, bimekizumab and JAKis after 16 weeks [39–42]; and ixekizumab after 16-20 weeks ... Sin título.
    https://gd.eppo.int/taxon/HUMJA/download/datasheet_doc

  4. Sin título

     
    Tipo: Microsoft Word
    NICE recommends assessing response to TNFi after 12 weeks [38]; secukinumab, bimekizumab and JAKis after 16 weeks [39–42]; and ixekizumab after 16-20 weeks ... Sin título.
    https://sas-space.sas.ac.uk/6402/1/Mustafa%2C%20Ahmet.docx

  5. Sin título

     
    Tipo: Microsoft Word
    NICE recommends assessing response to TNFi after 12 weeks [38]; secukinumab, bimekizumab and JAKis after 16 weeks [39–42]; and ixekizumab after 16-20 weeks ... Sin título.
    https://pure.southwales.ac.uk/files/10203144/C_Transcript.docx

  6. Sin título

     
    Tipo: Microsoft Word
    NICE recommends assessing response to TNFi after 12 weeks [38]; secukinumab, bimekizumab and JAKis after 16 weeks [39–42]; and ixekizumab after 16-20 weeks ... Sin título.
    https://researchportal.bath.ac.uk/files/220168070/REVISED2_Manuscript_text_UNmarked.docx

  7. Sin título

     
    Tipo: Microsoft Word
    NICE recommends assessing response to TNFi after 12 weeks [38]; secukinumab, bimekizumab and JAKis after 16 weeks [39–42]; and ixekizumab after 16-20 weeks ... Sin título.
    https://ssec.si.edu/sites/default/files/other/lightourway/Light%20Up%20the%20Cave%20alt%20text_km%20mjbr.docx

  8. Sin título

     
    Tipo: Microsoft Word
    NICE recommends assessing response to TNFi after 12 weeks [38]; secukinumab, bimekizumab and JAKis after 16 weeks [39–42]; and ixekizumab after 16-20 weeks ... Sin título.
    http://www.unice.fr/ed-svs/fr/site/convention-codirection-internationale.docx

  9. Sin título

     
    Tipo: Microsoft Word
    NICE recommends assessing response to TNFi after 12 weeks [38]; secukinumab, bimekizumab and JAKis after 16 weeks [39–42]; and ixekizumab after 16-20 weeks ... Sin título.
    https://www.researchgate.net/profile/Sizheng-Zhao/publication/390628864_The_2025_British_Society_for_Rheumatology_guideline_for_the_treatment_of_axial_spondyloarthritis_with_biologic_and_targeted_synthetic_DMARDs/links/67ffd5a9ded43315572a5339/The-2025-British-Society-for-Rheumatology-guideline-for-the-treatment-of-axial-spondyloarthritis-with-biologic-and-targeted-synthetic-DMARDs?origin=scientificContributions

Libro en otros formatos:


Arriba